

学校编码: 10384

密级\_\_\_\_\_

学号: 24520111153399

厦 门 大 学

硕 士 学 位 论 文

构建 TNFAIP8 干扰及原核表达载体并制备  
TNFAIP8 抗体

Construct the TNFAIP8 interference and prokaryotic  
expression vector and prepare TNFAIP8 antibody

杨晶晶

指导教师姓名: 庄国洪 副教授

齐忠权 教 授

专 业 名 称: 药理学

论文提交日期: 2014 年 5 月

论文答辩日期: 2014 年 5 月

2014 年 5 月

## 厦门大学学位论文原创性声明

本人呈交的学位论文是本人在导师指导下,独立完成的研究成果。本人在论文写作中参考其他个人或集体已经发表的研究成果,均在文中以适当方式明确标明,并符合法律规范和《厦门大学研究生学术活动规范(试行)》。

另外,该学位论文为( )课题(组)的研究成果,获得( )课题(组)经费或实验室的资助,在( )实验室完成。(请在以上括号内填写课题或课题组负责人或实验室名称,未有此项声明内容的,可以不作特别声明。)

声明人(签名):

年 月 日

## 厦门大学学位论文著作权使用声明

本人同意厦门大学根据《中华人民共和国学位条例暂行实施办法》等规定保留和使用此学位论文，并向主管部门或其指定机构送交学位论文（包括纸质版和电子版），允许学位论文进入厦门大学图书馆及其数据库被查阅、借阅。本人同意厦门大学将学位论文加入全国博士、硕士学位论文共建单位数据库进行检索，将学位论文的标题和摘要汇编出版，采用影印、缩印或者其它方式合理复制学位论文。

本学位论文属于：

（        ） 1.经厦门大学保密委员会审查核定的保密学位论文，  
于     年    月    日解密，解密后适用上述授权。

（        ） 2.不保密，适用上述授权。

（请在以上相应括号内打“√”或填上相应内容。保密学位论文应是已经厦门大学保密委员会审定过的学位论文，未经厦门大学保密委员会审定的学位论文均为公开学位论文。此声明栏不填写的，默认为公开学位论文，均适用上述授权。）

声明人（签名）：

年    月    日

## 摘要

恶性肿瘤的发病率在世界范围内逐渐增高，而肿瘤的发生与一些肿瘤相关基因的改变相关，即癌基因与抑癌基因之间的平衡被打破造成的，非正常的生活方式、各种污染、激素变化、辐射、药物及基因等因素也是其诱因。

肿瘤坏死因子  $\alpha$  诱导蛋白 8 ( tumor necrosis factor  $\alpha$  induced protein-8, TNFAIP8 ) 是转录因子 NF- $\kappa$ B 可诱导的抗凋亡，致癌分子，分子量为 21kD 的胞浆蛋白。TNFAIP8 在肾癌及乳腺癌中高表达，过表达的 TNFAIP8 可导致乳腺癌、肺癌、肾细胞癌和食管鳞状细胞癌的进展，因其在细胞凋亡信号转导、肿瘤发生、侵袭及转移过程中具有重要调控作用而逐渐成为研究的热点。

为了进一步探索 TNFAIP8 在肿瘤发生和发展中的作用，我们拟构建其原核表达载体 TNFAIP8-PET-22b(+), 并表达纯化 TNFAIP8 蛋白。同时应用 TNFAIP8 蛋白免疫新西兰兔制备其多抗；使用 TNFAIP8 蛋白免疫 BALB/c 鼠融合并筛选杂交瘤细胞株、制备其单克隆抗体并鉴定抗体活性。

为了深入的探究干扰表达 TNFAIP8 后对肿瘤细胞的影响及其在肿瘤发生发展中的作用机制，我们设计并合成针对人 TNFAIP8 基因的 RNA 干扰序列，将其连接到 pSIREN-RetroQ 载体，构建 TNFAIP8 基因的 shRNA 重组质粒。经脂质体法转染 TNFAIP8-shRNA-pSIREN-RetroQ 干扰质粒、载体 pSIREN-RetroQ 质粒和 GFP-pSIREN-RetroQ 质粒至人肺腺癌细胞系 A549 细胞，并检测其干扰 TNFAIP8 表达的效果。荧光显微镜检测带有 GFP 基因质粒的表达情况以确认转染效率，应用 RT-PCR 以及 Western-Blot 方法检测并筛选在 mRNA 和蛋白水平干扰效率最佳的干扰片段。通过干扰 A549 细胞 TNFAIP8 蛋白的表达，确定 TNFAIP8 对肿瘤细胞生长的影响。

研究结果表明，我们成功构建 TNFAIP8-PET-22b (+) 表达载体，筛选到 TNFAIP8 高表达菌株，确定最适诱导条件为 0.6 mM IPTG 诱导 10h，纯化复性后的 TNFAIP8 蛋白纯度在 90% 以上。Western-Blot 结果表明所纯化的蛋白可与抗 TNFAIP8 抗体发生特异结合。TNFAIP8 免疫新西兰兔获得 2 株多克隆抗体，其效价分别为  $10^4$  和  $10^5$ 。检测得出制备的多克隆抗体不可以应用于 Western-Blot

和免疫组化。TNFAIP8 免疫 BALB/c 鼠后融合筛选出 8 株杂交瘤细胞株，其分泌的抗体效价分别是  $10^4$ 、 $10^6$ 、 $10^4$ 、 $10^5$ 、 $10^6$ 、 $10^4$ 、 $10^4$  和  $10^6$ ，经鉴定 1 号至 5 号可应用于 Western-Blot。

针对 TNFAIP8 基因的不同片段，我们成功设计和构建了三条干扰质粒 TNFAIP8-shRNA-pSIREN-RetroQ。GFP-pSIREN-RetroQ 对照质粒转染 A549 细胞 48h 后，荧光显微镜下可观察到大量绿色荧光蛋白的表达，其转染效率为 80%，经 RT-PCR 和 Western-Blot 证实 TNFAIP8-shRNA1-pSIREN-RetroQ 能有效干扰并显著抑制细胞内 TNFAIP8 基因的表达。应用终浓度  $100\mu\text{g/mL}$  的 aDR<sub>5</sub>ScFv 分别作用转染 TNFAIP8-shRNA1 干扰质粒和空载质粒的 A549 细胞 16h，流式结果显示前者早、晚期凋亡率均有增加，前者凋亡率为 36.3% 高于后者 11.53%，说明 TNFAIP8 具有抑制肿瘤细胞凋亡的作用。

本实验成功获得 TNFAIP8-PET-22b (+) 原核表达载体，纯化到 TNFAIP8 蛋白；获得 2 株 TNFAIP8 多克隆抗体；筛选的 5 株单克隆抗体可用于 Western-Blot 检测；成功获得 TNFAIP8-shRNA-pSIREN-RetroQ 干扰质粒；通过流式检测发现降低 TNFAIP8 表达可以提高细胞对 aDR<sub>5</sub>ScFv 诱导凋亡的敏感性。

**关键词：**原核构建表达 TNFAIP8 RNA 干扰 凋亡

## Abstract

Irregular lifestyles, pollution, radiation, hormone changes, drugs, genes and other factors are causing the incidencement of growing malignant tumors all over the world, while cancers are due to the changes of tumor-related genes, that is breaking the balance between oncogenes and tumor suppressor genes.

Tumor necrosis factor alpha induced protein 8 (tumor necrosis factor- $\alpha$  induced protein-8, TNFAIP8, TNFAIP8) was a 21kDa cytoplasmic protein who can induce the apoptosis and carcinogenic, also can be induced by transcription factor NF- $\kappa$ B. TNFAIP8 was highly expressed in renal cell carcinoma and breast carcinoma, overexpression of TNFAIP8 can lead to breast cancer, lung cancer, renal cell carcinoma and squamous cell carcinoma of the esophagus. TNFAIP8 become the hot topic of research because it has an important regulating role in the process of its signal transduction in cell apoptosis, carcinogenesis, invasion and metastasis in tumors.

In order to further explore the role of TNFAIP8 in the tumorigenesis and development of tumors, we plan to construct prokaryotic expression vector TNFAIP8-PET-22b (+), express and purify TNFAIP8 protein. Immune the New Zealand rabbits and with purified protein TNFAIP8 to prepare the corresponding titer polyclonal antibody and detect its activity. Prepare monoclonal antibody by using TNFAIP8 protein immune BALB/c mice screen mice fusion hybridoma cell lines and identify the activity of it.

According to the characteristics of shRNA and in order to further explore the effects on tumor cells after interference the expressing of TNFAIP8, we build shRNA recombinant plasmid targeting human TNFAIP8 gene by designing and synthesizing RNA interference on TNFAIP8 gene sequence and connect it to the pSIREN-RetroQ carrier. Transfection TNFAIP8-shRNA-pSIREN RetroQ interference plasmid, carrier PSIREN RetroQ plasmid and GFP-pSIREN-RetroQ plasmid to human lung adenocarcinoma cells A549 cells by the method of liposome

and detect the interference on TNFAIP8 expression. Detect the expression of GFP gene to confirm the transfection efficiency by fluorescence microscope and filter out the highest interference efficiency plasmid by detecting the mRNA and protein levels using RT-PCR and Western-Blot methods. Determine TNFAIP8 effects on tumor cell growth by interfering TNFAIP8 protein expression in A549 cells.

Sequencing results showing that we successfully built TNFAIP8-PET-22b (+) expression vector and selected the high expression bacterial by inducing strain. Conform the optimum condition was 0.6 mM IPTG induct for 10 h and purified TNFAIP8 protein was over 90%. Western-Blot results showed that the purified protein can be specifically combined with TNFAIP8 antibody. Immune the New Zealand rabbit and obtained 2 polyclonal antibodies whose strains titer were respectively  $10^4$  and  $10^5$ . The prepared polyclonal antibodies cannot be applied to Western-Blot and Immunohistochemistry. Using TNFAIP8 protein immune BALB/c mouse to integrate and filter out 8 hybridoma cell strains, the titers of their secretory antibodies were respectively  $10^4$ ,  $10^6$ ,  $10^4$ ,  $10^6$ ,  $10^6$ ,  $10^4$ ,  $10^6$  and  $10^4$ . The No. 1 to No. 5 monoclonal antibodies could be applied to Western-Blot. Successfully built three interference TNFAIP8 gene plasmid TNFAIP8-shRNA-pSIREN-RetroQ which were consistent with the expected sequences. The green fluorescent protein expression were detected by fluorescence microscope 48 h after GFP-pSIREN-RetroQ plasmid was transfected to A549 cells and the transfection efficiency was 80%. RT-PCR and Western-Blot results confirmed TNF-AIP8-shRNA1-pSIREN-RetroQ could effectively interference and significantly inhibit the expression of TNFAIP8. Flow cytometry result showed that with  $100\mu\text{g/mL}$  aDR5ScFv acted 16h on the A549 cells separately 24h after transfected with TNFAIP8-shRNA1 interference plasmid and no-load plasmid, the late and early apoptosis rates of the former one was rising, the former apoptosis was 36.3% higher than the latter 11.53%, explaining that TNFAIP8 has effects on inhibiting tumor cell apoptosis.

This experiment successfully acquired the high expression TNFAIP8-PET-22b(+) prokaryotic expression vector and purified high purity TNFAIP8 protein. Obtained high titer polyclonal antibody and the screened 5 monoclonal antibody

could be applied to Western-Blot. Successfully built TNFAIP8-shRNA-pSIREN-RetroQ interference plasmid, which could significantly reduce the TNFAIP8 expression both in gene and protein levels. Flow cytometry testing found reduced the expression of TNFAIP8 could improve the sensitivity of cells toward apoptosis induced by aDR5ScFv.

**Keywords:** prokaryotic construct and expression;TNFAIP8;RNA interference; apoptosis.

廈門大學博碩士論文摘要庫



## 目 录

摘 要.....	I
目 录.....	VI
第一章 前言 .....	1
1.1 肿瘤的诱因 .....	1
1.1.1 吸烟.....	1
1.1.2 饮食因素 .....	2
1.1.3 肥胖和锻炼.....	2
1.1.4 饮酒 .....	3
1.1.5 传染性病原体 .....	3
1.1.6 化学元素和污染.....	4
1.1.7 生殖因素和外源激素 .....	4
1.1.8 能量和生长因子.....	4
1.1.9 电离辐射和非电离辐射 .....	5
1.1.10 治疗和药物作用 .....	5
1.1.11 基因因素 .....	6
1.2 肿瘤的治疗 .....	6
1.2.1 针对不同癌症的个体化治疗 .....	6
1.2.2 端粒酶的免疫治疗 .....	7
1.2.3 恶性肿瘤的磁介导热疗 .....	7
1.2.4 声动力治疗 .....	8
1.2.5 纳米技术治疗 .....	8
1.2.6 细胞免疫治疗和干细胞移植治疗 .....	9
1.2.7 单克隆抗体治疗 .....	9
1.2.8 RNAi 治疗 .....	10

<b>1.3 TNFAIP8 家族的研究现状.....</b>	<b>10</b>
1.3.1 TNFAIP8 家族成员和结构 .....	11
1.3.2 TNFAIP8 各成员的分布 .....	11
1.3.3 TNFAIP8 与肿瘤 .....	12
<b>1.4 RNA 干扰的研究现状.....</b>	<b>13</b>
1.4.1 RNA 干扰的作用和机制 .....	13
1.4.2 RNAi 的分类 .....	14
1.4.2.1 miRNA .....	14
1.4.2.2 shRNA.....	17
1.4.2.3 dsRNA.....	19
1.4.2.4 siRNA .....	19
1.4.3 RNAi 与肿瘤的关系 .....	19
<b>1.5 实验方案设计 .....</b>	<b>20</b>
1.5.1 研究目的和意义.....	20
1.5.2 研究目标.....	20
1.5.3 研究内容.....	20
<b>第二章 TNFAIP8 原核表达质粒的构建表达及其抗体的筛选 .....</b>	<b>22</b>
<b>2.1 材料和方法 .....</b>	<b>22</b>
2.1.1 材料.....	22
2.1.1.1 TNFAIP8 cDNA、双酶切引物、质粒载体 .....	22
2.1.1.2 主要试剂及耗材.....	22
2.1.1.3 主要仪器及设备.....	23
2.1.1.4 主要溶液的配制.....	23
2.1.2 实验方法.....	29
2.1.2.1 根据 TNFAIP8 序列及 PET-22b(+)特性设计引物.....	29
2.1.2.2 表达载体的构建与转化.....	30
2.1.2.3 重组子的筛选和序列分析.....	33
2.1.2.4 目的蛋白在大肠杆菌中的表达.....	34

2.1.2.5 目的蛋白的过柱纯化和复性.....	35
2.1.2.6 Western-Blot 检测 TNFAIP8 蛋白表达.....	37
2.1.2.7 多克隆抗体的制备和特性鉴定.....	38
2.1.2.8 单克隆抗体的制备和特性鉴定.....	39
<b>2.2 结果与分析 .....</b>	<b>40</b>
2.2.1 PET22b(+)质粒图谱和酶切位点.....	40
2.2.2 TNFAIP8 PCR 引物的设计及扩增.....	40
2.2.3 双酶切及回收后连接.....	41
2.2.4 重组子的筛选和测序.....	41
2.2.4.1 重组子的初筛.....	41
2.2.4.2 重组子的复筛.....	42
2.2.4.3 筛选阳性菌落的测序.....	42
2.2.5 目的蛋白的表达.....	43
2.2.5.1 高表达菌种的筛选.....	43
2.2.5.2 高表达菌株最适 IPTG 浓度的确定.....	43
2.2.5.3 最适诱导时间的确定.....	44
2.2.5.4 目的蛋白的高效表达和纯化.....	44
2.2.6 TNFAIP8 蛋白的 Western-Blot 鉴定.....	45
2.2.7 多克隆抗体的制备和特性鉴定.....	45
2.2.7.1 多克隆抗体的 ELISA 鉴定.....	45
2.2.7.2 多克隆抗体的 Western-Blot 鉴定.....	46
2.2.7.3 多克隆抗体的免疫组化鉴定.....	46
2.2.8 单克隆抗体的制备和特性鉴定.....	46
2.2.8.1 单克隆抗体的 ELISA 鉴定.....	46
2.2.8.2 单克隆抗体的 Western-Blot 鉴定.....	46
<b>2.3 讨论.....</b>	<b>47</b>
<b>第三章 TNFAIP8 干扰质粒的构建及最佳干扰效率质粒的筛选 .....</b>	<b>51</b>
<b>3.1 材料与方法 .....</b>	<b>51</b>
3.1.1 实验材料.....	51

3.1.1.1 质粒、引物、菌株和细胞.....	51
3.1.1.2 主要试剂及耗材.....	51
3.1.1.3 主要仪器及设备.....	52
3.1.1.4 主要溶液的配制.....	52
<b>3.1.2 实验方法.....</b>	<b>55</b>
3.1.2.1 质粒 pSIREN-RetroQ 的转化.....	55
3.1.2.2 质粒 pSIREN-RetroQ 的提取.....	55
3.1.2.3 质粒 pSIREN-RetroQ 双酶切及回收.....	57
3.1.2.4 RNA 干扰片段的设计与合成.....	58
3.1.2.5 互补片段退火.....	59
3.1.2.6 目的基因与载体的连接.....	60
3.1.2.7 重组质粒的转化、鉴定及测序.....	60
3.1.2.8 人肺腺癌细胞系 A549 细胞培养、转染及检测.....	61
<b>3.2 结果与分析.....</b>	<b>65</b>
3.2.1 pSIREN-RetroQ 质粒图谱和酶切位点.....	65
3.2.2 干扰互补片段的退火及鉴定.....	66
3.2.3 pSIREN-RetroQ 质粒酶切回收及连接.....	66
3.2.4 TNFAIP8-shRNA-pSIREN-RetroQ 重组质粒阳性克隆初筛鉴定.....	67
3.2.5 TNFAIP8-shRNA-pSIREN-RetroQ 重组质粒阳性克隆复筛鉴定.....	67
3.2.6 TNFAIP8-shRNA-pSIREN-RetroQ 测序结果比对.....	68
3.2.9 Western-Blot 检测 TNFAIP8-shRNA-pSIREN-RetroQ 质粒干扰效率.....	69
3.2.10 流式检测 TNFAIP8-shRNA-pSIREN-RetroQ 干扰质粒活性.....	70
<b>3.3 讨论.....</b>	<b>71</b>
<b>总 结.....</b>	<b>73</b>
<b>参考文献.....</b>	<b>74</b>
<b>致 谢.....</b>	<b>84</b>

## Table of contents

<b>Table of contents .....</b>	<b>X</b>
<b>Chapter 1 Introduction .....</b>	<b>1</b>
<b>1.1 Tumor incentives .....</b>	<b>1</b>
1.1.1 Smoke .....	1
1.1.2 Diet factor .....	2
1.1.3 Adiposity and exercise .....	2
1.1.4 Drunk .....	3
1.1.5 Infectious pathogens .....	3
1.1.6 Chemistry elements and pollution .....	4
1.1.7 Reproductive factors and exogenous hormone .....	4
1.1.8 Energy and growth factor .....	4
1.1.9 Ionizing and non ionizing radiation .....	5
1.1.10 Therapy and medicine effect .....	5
1.1.11 Gene factor .....	6
<b>1.2 Cancer therapy .....</b>	<b>6</b>
1.2.1 Individual treatment toward different cancers .....	6
1.2.2 Immunotherapy of telomerase .....	7
1.2.3 Magnetic mediated hyperthermia toward malignancy .....	7
1.2.4 Sonodynamic therapy .....	8
1.2.5 Nano technology therapy .....	8
1.2.6 Cellular immune therapy .....	9
1.2.7 Monoclonal antibody therapy .....	9
1.2.8 RNAi therapy .....	10
<b>1.3 The research status of TNFAIP8 family .....</b>	<b>10</b>
1.3.1 The members and structure of TNFAIP8 family .....	11
1.3.2 The distribution of TNFAIP8 family members .....	11

1.3.3 TNFAIP8 and cancer.....	12
<b>1.4 Current status of research on RNA interference.....</b>	<b>13</b>
1.4.1 The role and mechanism of RNA interference.....	13
1.4.2 The classification of RNAi .....	14
1.4.2.1 miRNA .....	14
1.4.2.2 shRNA.....	17
1.4.2.3 dsRNA.....	19
1.4.2.4 siRNA .....	19
1.4.3 The relationship between RNAi and tumor .....	19
<b>1.5 The designation of experiment scheme .....</b>	<b>20</b>
1.5.1 The purpose and significance of the thesis .....	20
1.5.2 The target of the thesis .....	20
1.5.3 The contents of the thesis .....	20
<b>Chapter 2 The second chapter Construct and expres the TNFAIP8 prokaryotic expression plasmid and screen its high specific antibody .....</b>	<b>22</b>
<b>2.1 Materials and methods .....</b>	<b>22</b>
2.1.1 Materials.....	22
2.1.1.1 TNFAIP8 cDNA,plasmid vector.....	22
2.1.1.2 Main reagents and consumables .....	22
2.1.1.3 The main instruments and equipments.....	23
2.1.1.4 The preparation of the main solution .....	23
2.1.2 empirical method .....	29
2.1.2.1 Design characteristics primers according to PET-22b (+)and the sequences of TNFAIP8 .....	29
2.1.2.2 Construct of vector expression and transformation .....	30
2.1.2.3 Screen and sequence analysis of recombinant .....	33
2.1.2.4 The expression of recombinant protein in E. coli .....	34
2.1.2.5 Column purification and renaturation of target protein .....	35

---

2.1.2.6 Detect the TNFAIP8 protein expression by Western-Blot .....	37
2.1.2.7 Preparation and characterization of polyclonal antibody.....	38
2.1.2.8 Preparation and characterization of monoclonal antibody.....	39
<b>2.2 Results and analysis .....</b>	<b>40</b>
<b>2.2.1 The profiles and restriction enzyme sites of PET22b (+) plasmid .....</b>	<b>40</b>
<b>2.2.2 Design and amplificate of TIPE PCR primer .....</b>	<b>40</b>
<b>2.2.3 Connect the recovered double enzyme digestion products.....</b>	<b>41</b>
<b>2.2.4 Screen and sequence the recombinant.....</b>	<b>41</b>
2.2.4.1 Screen recombinants .....	41
2.2.4.2 Second screen recombinants .....	42
2.2.4.3 Sequencing screened positive colonies .....	42
<b>2.2.5 Express the target protein.....</b>	<b>43</b>
2.2.5.1 Select the high expression bacterial .....	43
2.2.5.2 Optimizate the optimal concentration IPTG of high expression strain....	43
2.2.5.3 Optimizate the optimal induction time .....	44
2.2.5.4 High effective expression and purification of target protein .....	44
<b>2.2.6 Identificate the TNFAIP8 protein by Western-Blot .....</b>	<b>45</b>
<b>2.2.7 Preparation and characterization of polyclonal antibody .....</b>	<b>45</b>
2.2.7.1 Identificate the polyclonal antibody by ELISA .....	45
2.2.7.2 Identificate the polyclonal antibody by Western-Blot .....	46
2.2.7.3 Immunohistochemical identification on the polyclonal antibody.....	46
<b>2.2.8 Preparation and characterization of monoclonal antibody.....</b>	<b>46</b>
2.2.8.1 Identificate the monoclonal antibody by ELISA .....	46
2.2.8.2 Identificate the monoclonal antibody by Western-Blot .....	46
<b>2.3 discussion .....</b>	<b>47</b>
<b>Chapter 3 Design and construct the TNFAIP8 interference plasmid and screen the high efficiency interference plasmid .....</b>	<b>51</b>
<b>3.1 Materials and methods .....</b>	<b>51</b>

<b>3.1.1 Materials and methods.....</b>	<b>51</b>
3.1.1.1 Plasmid, primer, strains and cells.....	51
3.1.1.2 Main reagents and consumables .....	51
3.1.1.3 The main instruments and equipments.....	52
3.1.1.4 Preparation of the main solution .....	52
<b>3.1.2 Empirical methods .....</b>	<b>55</b>
3.1.2.1 Rransform the pSIREN-RetroQ plasmid .....	55
3.1.2.2 Extract pSIREN-RetroQ plasmid.....	55
3.1.2.3 Recovery the double enzyme digested pSIREN-RetroQ plasmid .....	57
3.1.2.4 Design and synthesis the RNA  interference segment .....	58
3.1.2.5 Anneal the complementary strand.....	59
3.1.2.6 Connect the objective gene and carrier .....	60
3.1.2.7 Transformat,identificate and sequence the recombinant plasmid .....	60
3.1.2.8 Transfect,detect and culture the human lung adenocarcinoma cell line A549 cells .....	61
<b>3.2 Results and analysis .....</b>	<b>65</b>
3.2.1 The profiles and restriction enzyme sites of pSIREN-RetroQ plasmid....	65
3.2.2 Identify the annealed complementary strand .....	66
3.2.3 Connect and recovery the double enzyme digested pSIREN-RetroQ plasmid .....	66
3.2.4 Screen the positive recombined TNFAIP8-shRNA-pSIREN-RetroQ plasmid .....	67
3.2.5 Second screen the positive recombined TNFAIP8-shRNA-pSIREN -RetroQ plasmid .....	67
3.2.6 Compare theTNFAIP8-shRNA-pSIREN-RetroQ sequencing results .....	68
3.2.7 Culture and transfect the human lung adenocarcinoma cell line A549 cells.....	68
3.2.8 Detect the TNFAIP8-shRNA-pSIREN-RetroQ plasmid interference efficiency by RT-PCR.....	69
3.2.9 Detect the TNFAIP8-shRNA-pSIREN-RetroQ plasmid interference efficiency by Western-Blot .....	69
3.2.10 Detect the biological activity of TNFAIP8-shRNA-pSIREN-RetroQ interference plasmid by flow cytometry .....	70



Degree papers are in the "[Xiamen University Electronic Theses and Dissertations Database](#)". Full texts are available in the following ways:

1. If your library is a CALIS member libraries, please log on <http://etd.calis.edu.cn/> and submit requests online, or consult the interlibrary loan department in your library.
2. For users of non-CALIS member libraries, please mail to [etd@xmu.edu.cn](mailto:etd@xmu.edu.cn) for delivery details.

廈門大學博碩士論文摘要庫